Mean serum K+ results in a retrospective EHR analysis of more than 500 ESRD patients on dialysis1
- Approximately 75% of patients had a baseline K+ of ≥5.5 mEq/L
- 61% (n=322) started and remained on VELTASSA 8.4 g once daily
- 75% of patients remained on VELTASSA for at least 80% of the study period
- Safety was not evaluated in this retrospective analysis
Real-world data were retrospectively collected, are observational in nature, and are not based on controlled clinical studies.
Dialysis retrospective study design
Treatment of hyperkalemia in hemodialysis patients who newly initiated VELTASSA in real-world practice
In a retrospective observational study using Electronic Health Record (EHR) data (N=527), patients (≥18 years) receiving hemodialysis at a large U.S. dialysis provider between December 21, 2015, and December 20, 2016, were identified. K+ values were summarized in 6 sequential 30-day periods, 3 preceding and 3 following VELTASSA initiation. Patients had at least 24 hemodialysis treatments in the 3 months prior to VELTASSA initiation. Of 527 patients studied, the mean age was 59 years, 57% were men, 70% were white/Hispanic, and 17% were black.